Date: 2012-02-14
Type of information: Commercialisation agreement
Compound: Ruconest® (Rhucin® in non-European territories - conestat alfa)
Company: Pharming (The Netherlands) Transmedic Pte (Singapore)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: commercialisation
Action mechanism: Ruconest® is a recombinant version of the human protein C1 inhibitor (C1INH). It is produced through Pharming’s proprietary technology in milk of transgenic rabbits.
Disease: acute angioedema attacks in patients with Hereditary Angioedema (HAE)
Details: Pharming has entered into an agreement with Transmedic Pte Ltd, a privately owned Singapore based specialty healthcare company, for the commercialization of Ruconest® (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in parts of South- East Asia. The South- East Asian territories covered under this agreement include Brunei, Indonesia, Malaysia, Philippines, Singapore, and Thailand. Under the agreement, Transmedic will drive the respective regulatory approvals and purchase its commercial supplies of Ruconest® from Pharming at a fixed transfer price.
Financial terms:
Latest news:
